IBRX ImmunityBio Forecast, Technical & Fundamental Analysis
ImmunityBio Inc is a biotechnology company focused on developing and commercializing next-generation immunotherapies designed to activate the patient's immune system and provide durable protection against cancer and infectious diseases... Show more
IBRX is expected to report earnings to fall 86.69% to -8 cents per share on August 12
Q2'26
Est.
$-0.08
Q1'26
Missed
by $0.55
Q4'25
Beat
by $0.05
Q3'25
Beat
by $0.04
Q2'25
Beat
by $0.01
The last earnings report on May 07 showed earnings per share of -62 cents, missing the estimate of -7 cents. With 6.06M shares outstanding, the current market capitalization sits at 9.23B.
A.I.dvisor indicates that over the last year, IBRX has been loosely correlated with AXON. These tickers have moved in lockstep 48% of the time. This A.I.-generated data suggests there is some statistical probability that if IBRX jumps, then AXON could also see price increases.
IBRX in +7.82% Uptrend, growing for three consecutive days on July 02, 2026
Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where IBRX advanced for three days, in of 241 cases, the price rose further within the following month. The odds of a continued upward trend are .
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on June 18, 2026. You may want to consider a long position or call options on IBRX as a result. In of 101 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
The Moving Average Convergence Divergence (MACD) for IBRX just turned positive on June 22, 2026. Looking at past instances where IBRX's MACD turned positive, the stock continued to rise in of 55 cases over the following month. The odds of a continued upward trend are .
IBRX moved above its 50-day moving average on June 24, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for IBRX crossed bullishly above the 50-day moving average on June 30, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In of 16 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .
Bearish Trend Analysis
The 10-day RSI Indicator for IBRX moved out of overbought territory on July 06, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 19 similar instances where the indicator moved out of overbought territory. In of the 19 cases, the stock moved lower in the following days. This puts the odds of a move lower at .
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In of 48 cases where IBRX's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are .
IBRX broke above its upper Bollinger Band on June 24, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for IBRX entered a downward trend on June 25, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.000) is normal, around the industry mean (22.980). P/E Ratio (0.000) is within average values for comparable stocks, (38.292). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.534). IBRX has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.038). P/S Ratio (60.241) is also within normal values, averaging (407.380).
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. IBRX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. IBRX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
